- Home
- HCWB vs BCDA Comparison
HCWB vs BCDA Comparison
Compare HCWB & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- BCDA
- Stock Information
- Founded
- HCWB 2018
- BCDA N/A
- Country
- HCWB United States
- BCDA United States
- Employees
- HCWB N/A
- BCDA N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- HCWB Health Care
- BCDA Health Care
- Exchange
- HCWB Nasdaq
- BCDA Nasdaq
- Market Cap
- HCWB 10.8M
- BCDA 11.3M
- IPO Year
- HCWB 2021
- BCDA N/A
- Fundamental
- Price
- HCWB $5.59
- BCDA $2.16
- Analyst Decision
- HCWB Strong Buy
- BCDA Strong Buy
- Analyst Count
- HCWB 1
- BCDA 1
- Target Price
- HCWB $35.00
- BCDA $25.00
- AVG Volume (30 Days)
- HCWB 5.7M
- BCDA 45.6K
- Earning Date
- HCWB 08-18-2025
- BCDA 11-12-2025
- Dividend Yield
- HCWB N/A
- BCDA N/A
- EPS Growth
- HCWB N/A
- BCDA N/A
- EPS
- HCWB N/A
- BCDA N/A
- Revenue
- HCWB $832,841.00
- BCDA N/A
- Revenue This Year
- HCWB $178.36
- BCDA N/A
- Revenue Next Year
- HCWB N/A
- BCDA N/A
- P/E Ratio
- HCWB N/A
- BCDA N/A
- Revenue Growth
- HCWB N/A
- BCDA N/A
- 52 Week Low
- HCWB $2.77
- BCDA $1.63
- 52 Week High
- HCWB $100.80
- BCDA $3.26
- Technical
- Relative Strength Index (RSI)
- HCWB 60.31
- BCDA 59.44
- Support Level
- HCWB $3.25
- BCDA $1.90
- Resistance Level
- HCWB $6.66
- BCDA $2.29
- Average True Range (ATR)
- HCWB 0.77
- BCDA 0.09
- MACD
- HCWB -0.05
- BCDA 0.04
- Stochastic Oscillator
- HCWB 57.07
- BCDA 66.67
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).